Search results
Apr 30, 2024 · The Moderna vaccine is an mRNA vaccine, similar to the one developed by Pfizer. The technology behind these vaccines has been around for about three decades and shown promise in preventing notoriously difficult-to-prevent diseases—even cancer.
Nov 1, 2023 · Information about Moderna COVID-19 Vaccine, Bivalent. Updated, bivalent mRNA COVID-19 vaccines are now FDA-authorized for all doses for individuals ages 6 months and older.
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
Moderna's mission is to deliver the greatest possible impact to people through mRNA medicines.
- www.who.int
- › Newsroom
- › Feature stories
- › Detail
Aug 18, 2022 · The Moderna vaccine after two doses and a first booster dose has been shown to have very high effectiveness against severe disease, hospitalizations and death, and modest effectiveness against symptomatic illness.
Dec 22, 2020 · Moderna’s mRNA vaccine is the second COVID-19 vaccine to be authorized and fully approved for use in the U.S. Here, we give a rundown of basic facts about the vaccine and an overview of how...
Oct 17, 2023 · It’s a mRNA vaccine that helps prevent COVID. The FDA approved the updated Moderna vaccine (Spikevax) for use in people who are at least 12 years old. It’s authorized for emergency use in people 6 months through 11 years old. People age 5 and older are eligible to receive 1 updated Moderna dose.
This Vaccine Information Fact Sheet for Recipients and Caregivers comprises the Fact Sheet for the authorized Moderna COVID-19 Vaccine and also includes information about the FDA-licensed...
Moderna’s vaccine requires two injections, given 28 days apart, to prime the immune system well enough to fight off the coronavirus. But because the vaccine is so new, researchers don’t know ...
- www.nih.gov
- › News & Events
- › News Releases
Dec 30, 2020 · The investigational vaccine known as mRNA-1273 was 94.1% efficacious in preventing symptomatic coronavirus disease 2019 (COVID-19), according to preliminary results from a Phase 3 clinical trial reported in the New England Journal of Medicine.
